Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases
- PMID: 18490245
- DOI: 10.1007/s12094-008-0198-5
Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases
Abstract
Objective: To assess the effectiveness of a single dose of radio therapy (8 Gy vs. 6 Gy) plus zoledronic acid in cancer patients with bone metastases in treating pain; quality of life, time to onset of skeletal events and functional status.
Material and methods: A total of 139 patients from 22 Spanish hospitals were randomly assigned to: Group A, administered a single dose of 8 Gy+zoledronic acid (4 mg iv, in 15-min infusions), and Group B, administered a single dose of 6 Gy+zoledronic acid (4 mg iv, in 15-min infusions). The main variable was pain, which was assessed with the Visual Analogue Pain Scale (VAS) in supine, seated and standing positions.
Results: There was a total of 118 patients for intention to treat (n=67 in Group A and n=51 in Group B). The most frequent primary neoplasms were the lung (29.66%), prostate (22.03%) and breast (21.19%). Sixty patients were analysed per protocol, n=34 in group A and n=26 in group B. Improvements were observed in the VAS scores for pain in all three positions. The mean time to onset of the event was greater (p=0.0211) in Group A than in Group B (122 vs. 81.62 days). Functional status improved in Group A, and quality of life improved in both groups.
Conclusion: The two groups achieved similar levels of pain control in supine, seated and standing positions. Quality of life also improved in both groups. However, the higher dose (8 Gy dose) in combination with zoledronic acid is associated with a longer period without skeletal events.
Similar articles
-
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425. JAMA. 2017. PMID: 28030702 Free PMC article. Clinical Trial.
-
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4. Epub 2013 Dec 11. Lancet Oncol. 2014. PMID: 24332514 Clinical Trial.
-
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.Br J Cancer. 2005 May 23;92(10):1869-76. doi: 10.1038/sj.bjc.6602551. Br J Cancer. 2005. PMID: 15870721 Free PMC article. Clinical Trial.
-
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.Pharmacoeconomics. 2008;26(3):251-68. doi: 10.2165/00019053-200826030-00007. Pharmacoeconomics. 2008. PMID: 18282018 Review.
-
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.Drugs. 2008;68(4):507-34. doi: 10.2165/00003495-200868040-00010. Drugs. 2008. PMID: 18318568 Review.
Cited by
-
Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases.Support Care Cancer. 2012 Apr;20(4):657-77. doi: 10.1007/s00520-011-1356-9. Support Care Cancer. 2012. PMID: 22302082 Free PMC article. Review.
-
Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.Support Care Cancer. 2012 Nov;20(11):2985-98. doi: 10.1007/s00520-012-1563-z. Epub 2012 Sep 7. Support Care Cancer. 2012. PMID: 22956190 Free PMC article.
-
Chemotherapy- and irradiation-induced bone loss in adults with solid tumors.Curr Osteoporos Rep. 2015 Jun;13(3):140-5. doi: 10.1007/s11914-015-0266-z. Curr Osteoporos Rep. 2015. PMID: 25712619 Free PMC article. Review.
-
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.Support Care Cancer. 2015 Apr;23(4):1157-68. doi: 10.1007/s00520-014-2525-4. Epub 2014 Dec 23. Support Care Cancer. 2015. PMID: 25533578 Review.
-
Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Inflammopharmacology. 2013 Oct;21(5):339-63. doi: 10.1007/s10787-013-0183-7. Epub 2013 Aug 6. Inflammopharmacology. 2013. PMID: 23918298 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical